IGF1 and Duchenne muscular dystrophy: Neu REFIX an orally administrable, safe, allergen-free β-1,3-1,6 glucan, has demonstrated its potential as a disease-modifying therapeutic adjuvant for DMD in mdx mice model, by enhancing dystrophin and IGF-1 expression along with muscle regeneration markers MYH3 and CD44 in a short duration of 45 days.